TapewireFind a company

person · Reporting owner

Smith Kevin Raymond Merrill

Disclosed activity across 2 companies

Tapewire entity
2084
SEC CIK
0001802639

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Inogen IncINGN · Entity 2083Director · CEO and PresidentSeptember 01, 2026September 03, 2026
ONCOSEC MEDICAL IncONCS · Entity 117092DirectorJune 28, 2021June 29, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inogen Inc

Report date September 01, 2026 · Filed September 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect134,962 Reported balance After 2026-09-01 transaction · row 1
1 source row

Row 1 · 2026-09-01 · Grant · Acquired 1,500 · Balance 134,962

F1: Shares acquired through the Company's 2014 Employee Stock Purchase Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Shares acquired through the Company's 2014 Employee Stock Purchase Plan.

ONCOSEC MEDICAL Inc

Report date June 28, 2021 · Filed June 29, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2031-06-28Direct25,000 Reported balance After 2021-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-06-28 · Grant · Acquired 25,000 · Balance 25,000

F1: The option will vest in equal quarterly installments over the next year.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in equal quarterly installments over the next year.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2026 Filed Sep 3, 2026 21:00 UTC Inogen Inc INGN · Entity 2083 GrantCommon Stock 1,500 $5.33 $7,995.00
Disclosure

SEC source: 0001802639-26-000004 · ownership.xml · nonDerivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,962

F1 · shares: Shares acquired through the Company's 2014 Employee Stock Purchase Plan.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionRestricted Stock Unit · Derivative 30,012 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · derivative · entry 10

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,024

Underlying: Common Stock · 30,012 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F8 · derivative.exercise_date: 1/3rd of the restricted stock units vested on March 1, 2026 (the "2026 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2026 Vesting Commencement Date.

F8 · derivative.expiration_date: 1/3rd of the restricted stock units vested on March 1, 2026 (the "2026 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2026 Vesting Commencement Date.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionRestricted Stock Unit · Derivative 28,334 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · derivative · entry 9

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,333

Underlying: Common Stock · 28,334 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F7 · derivative.exercise_date: 1/3rd of the restricted stock units vested on March 1, 2025 (the "2025 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2025 Vesting Commencement Date.

F7 · derivative.expiration_date: 1/3rd of the restricted stock units vested on March 1, 2025 (the "2025 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2025 Vesting Commencement Date.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 Tax withholdingCommon Stock 14,511 $6.10 $88,517.10
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · nonDerivative · entry 7

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,462

F4 · shares: The reported shares were withheld to cover the reporting person's tax withholding liability in connection with a portion of a time-based restricted stock unit award that vested on March 1, 2026.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionCommon Stock 30,012 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · nonDerivative · entry 6

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,973

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 Tax withholdingCommon Stock 13,700 $6.10 $83,570.00
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · nonDerivative · entry 5

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,961

F4 · shares: The reported shares were withheld to cover the reporting person's tax withholding liability in connection with a portion of a time-based restricted stock unit award that vested on March 1, 2026.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionCommon Stock 28,334 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · nonDerivative · entry 4

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,661

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 Tax withholdingCommon Stock 16,374 $6.10 $99,881.40
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · nonDerivative · entry 3

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,327

F3 · shares: The reported shares were withheld to cover the reporting person's tax withholding liability in connection with the 2023 performance-based restricted stock unit award granted on November 10, 2023 and vested on March 1, 2026.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 GrantCommon Stock 32,725 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · nonDerivative · entry 2

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,701

F2 · shares: The reported securities represent shares earned and vested on March 1, 2026 based on achievement of the financial performance conditions for the 2025 fiscal year that were approved as part of the 2023 performance-based restricted stock unit award granted on November 10, 2023.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 GrantCommon Stock 685 $6.10 $4,178.50
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · nonDerivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,976

F1 · shares: Shares acquired through the Company's 2014 Employee Stock Purchase Plan.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:56 UTC Inogen Inc INGN · Entity 2083 GrantRestriced Stock Unit · Derivative 90,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088582 · ownership.xml · derivative · entry 8

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F6 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2027 (the "2027 Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2027 Vesting Commencement Date.

F6 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2027 (the "2027 Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2027 Vesting Commencement Date.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 21:06 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionRestricted Stock Unit · Derivative 28,334 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-305251 · ownership.xml · derivative · entry 3

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,333

Underlying: Common Stock · 28,334 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

F3 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 21:06 UTC Inogen Inc INGN · Entity 2083 Tax withholdingCommon Stock 13,817 $6.95 $96,028.15
Disclosure

SEC source: 0001193125-25-305251 · ownership.xml · nonDerivative · entry 2

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,291

F1 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2025.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 21:06 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionCommon Stock 28,334 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-305251 · ownership.xml · nonDerivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 01, 2025 Filed Sep 3, 2025 21:01 UTC Inogen Inc INGN · Entity 2083 GrantCommon Stock 1,500 $7.99 $11,985.00
Disclosure

SEC source: 0001802639-25-000004 · ownership.xml · nonDerivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,774

F1 · shares: Shares acquired through the Company's 2014 Employee Stock Purchase Plan.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 PurchaseCommon Stock 11,709 $8.56 $100,245.43
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · nonDerivative · entry 6

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,274

F5 · price: Represents the weighted average share price of an aggregate total of 11,709 shares sold in the price range of $8.455 to $8.6298 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionRestricted Stock Unit · Derivative 28,333 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · derivative · entry 8

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,667

Underlying: Common Stock · 28,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F8 · derivative.exercise_date: 1/3rd of the restricted stock units vested on March 1, 2025 (the "2025 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2025 Vesting Commencement Date.

F8 · derivative.expiration_date: 1/3rd of the restricted stock units vested on March 1, 2025 (the "2025 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2025 Vesting Commencement Date.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 Tax withholdingCommon Stock 26,097 $8.33 $217,388.01
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · nonDerivative · entry 5

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,565

F4 · shares: The reported shares were withheld to cover the reporting person's tax withholding liability in connection with the 2023 performance-based restricted stock unit award granted on November 10, 2023 and vested on March 1, 2025.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 GrantCommon Stock 53,975 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · nonDerivative · entry 4

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,662

F3 · shares: The reported securities represent shares earned and vested on March 1, 2025 based on achievement of the financial performance conditions for the 2024 fiscal year that were approved as part of the 2023 performance-based restricted stock unit award granted on November 10, 2023.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 Tax withholdingCommon Stock 13,700 $8.33 $114,121.00
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · nonDerivative · entry 3

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,687

F2 · shares: The reported shares were withheld to cover the reporting person's tax withholding liability in connection with a portion of a time-based restricted stock unit award that vested on March 1, 2025.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionCommon Stock 28,333 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · nonDerivative · entry 2

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,387

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 GrantCommon Stock 1,500 $8.33 $12,495.00
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · nonDerivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,054

F1 · shares: Shares acquired through the Company's 2014 Employee Stock Purchase Plan.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 23:41 UTC Inogen Inc INGN · Entity 2083 GrantRestricted Stock Unit · Derivative 90,036 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-032638 · ownership.xml · derivative · entry 7

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,036

Underlying: Common Stock · 90,036 shares

Expires not disclosed

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F7 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2026 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

F7 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2026 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

Read SEC document
December 01, 2024 Filed Dec 3, 2024 22:08 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionRestricted Stock Unit · Derivative 28,333 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-132860 · ownership.xml · derivative · entry 3

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,667

Underlying: Common Stock · 28,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

F3 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

Read SEC document
December 01, 2024 Filed Dec 3, 2024 22:08 UTC Inogen Inc INGN · Entity 2083 Tax withholdingCommon Stock 13,779 $9.71 $133,794.09
Disclosure

SEC source: 0000950170-24-132860 · ownership.xml · nonDerivative · entry 2

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,554

F1 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2024.

Read SEC document
December 01, 2024 Filed Dec 3, 2024 22:08 UTC Inogen Inc INGN · Entity 2083 Exercise / conversionCommon Stock 28,333 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-132860 · ownership.xml · nonDerivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 00:09 UTC Inogen Inc INGN · Entity 2083 GrantRestricted Stock Unit · Derivative 85,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026542 · ownership.xml · derivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2025, and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

F2 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2025, and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

Read SEC document
November 10, 2023 Filed Nov 13, 2023 22:30 UTC Inogen Inc INGN · Entity 2083 GrantRestricted Stock Unit · Derivative 85,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-055050 · doc4.xml · derivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

F2 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date.

Read SEC document
June 28, 2021 Filed Jun 29, 2021 19:41 UTC ONCOSEC MEDICAL Inc ONCS · Entity 117092 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $3.16 $0.00
Disclosure

SEC source: 0001493152-21-015619 · ownership.xml · derivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-06-28

F1 · derivative.exercise_date: The option will vest in equal quarterly installments over the next year.

Read SEC document
May 29, 2020 Filed Jun 3, 2020 21:07 UTC ONCOSEC MEDICAL Inc ONCS · Entity 117092 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.56 $0.00
Disclosure

SEC source: 0001493152-20-010502 · ownership.xml · derivative · entry 1

Smith Kevin Raymond Merrill · CIK 0001802639 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-04-14

F1 · date: The option grant was approved by the Issuer's Compensation Committee on April 14, 2020, subject to stockholder approval of an amendment to the Issuer's 2011 Incentive Plan to increase the number of authorized shares. The Issuer's stockholders approved the plan amendment on May 29, 2020.

F2 · derivative.exercise_date: The option vests quarterly over the next three years.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.